Alnylam Pharmaceuticals (ALNY) Curent Deferred Tax Liability (2014 - 2015)
Alnylam Pharmaceuticals' (ALNY) quarterly Curent Deferred Tax Liability came in at $9.4 million in Q3 2015, down 52.14% on a QoQ basis from $19.7 million in Q2 2015.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Curent Deferred Tax Liability (2014 - 2015) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 2 years of Curent Deferred Tax Liability data on file, last reported at $9.4 million in Q3 2015.
- Quarterly Curent Deferred Tax Liability changed N/A year-over-year to $9.4 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $9.4 million (changed N/A YoY) and the FY2014 annual result came in at $31.7 million, changed N/A from the prior year.
- Curent Deferred Tax Liability eased to $9.4 million in Q3 2015, from $19.7 million in the prior quarter.
- In the past five years, Curent Deferred Tax Liability ranged from a high of $33.7 million in Q1 2015 to a low of $9.4 million in Q3 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2015 | 9.41 Mn |
| Jun 30, 2015 | 19.65 Mn |
| Mar 31, 2015 | 33.67 Mn |
| Dec 31, 2014 | 31.67 Mn |